Study guide
18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD
Key Takeaways Explain This Topic AI
Classic psychedelics act as 5-HT2A receptor agonists, produce rapid tolerance, and do not cause physical dependence or a withdrawal syndrome.
The first-line management of a difficult psychedelic experience is a calm low-stimulus environment with reassurance, with benzodiazepines reserved for persistent severe agitation and antipsychotics generally avoided.
PCP intoxication is distinguished by vertical or rotary nystagmus, extreme agitation with analgesia, and violent behavior, and is managed with benzodiazepines in a low-stimulus setting.
MDMA can cause life-threatening hyponatremia from excessive free-water intake plus SIADH, and serotonin syndrome when combined with MAOIs or serotonergic agents.
Ketamine use disorder produces ulcerative cystitis with severe urinary frequency and reduced bladder capacity, which may be irreversible if use continues.
Last updated: September 2026
18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD
Quick Answer: Classic psychedelics (LSD, psilocybin, mescaline, DMT) are 5-HT2A agonists that produce rapid tolerance , no physical dependence and no withdrawal syndrome . A difficult experience is managed with reassurance in a calm, low-stimulus environment ; benzodiazepines are reserved for persistent severe agitation and antipsychotics are generally avoided . PCP produces vertical or rotary nystagmus , extreme agitation with analgesia , and violence. MDMA causes hyponatremia and serotonin syndrome . Chronic ketamine causes ulcerative cystitis . HPPD is persistent visual disturbance after psychedelic use.
1. Classic Serotonergic Psychedelics
- Agent Onset Duration Notes
- LSD 30 to 90 minutes 8 to 12 hours Active in microgram doses; extremely potent
- Psilocybin 20 to 40 minutes 4 to 6 hours Converted to psilocin; the subject of current clinical trials
Mescaline (peyote) 45 to 90 minutes 10 to 12 hours Sacramental use by the Native American Church is federally protected
DMT Seconds (smoked) 15 to 30 minutes In ayahuasca, combined with an MAOI (harmine), extending duration to hours
2C compounds, NBOMe Variable Variable NBOMe compounds are potent 5-HT2A agonists with a much narrower safety margin and reported deaths; often sold as LSD
Pharmacologic facts worth memorizing:
Tolerance develops within 3 to 4 consecutive days and is cross-tolerant among classic psychedelics, which structurally limits daily use.
There is no withdrawal syndrome and no physical dependence.
Classic psychedelics are physiologically well tolerated in healthy people; the danger is behavioral (trauma from impaired judgment) and psychiatric (precipitating or unmasking psychosis in vulnerable people).
Managing a difficult experience
Environment first. Quiet, dim, low-stimulus room; minimal personnel; one consistent person.
Talk-down. Reorient repeatedly to the fact that the experience is drug-induced, is time-limited, and will end.
Benzodiazepines only if reassurance fails and agitation threatens safety.
Avoid antipsychotics where possible: they can intensify dysphoria and, in an unknown ingestion, may worsen anticholinergic toxicity or lower the seizure threshold.
Consider NBOMe or an adulterant if the physiology is more severe than expected — hyperthermia, seizure or marked sympathomimetic toxicity is not typical of LSD or psilocybin.
2. MDMA
Complication Mechanism Management
Hyponatremia SIADH plus large free-water intake during prolonged dancing Fluid restriction; hypertonic saline for seizure or severe symptoms — a genuine emergency with several documented deaths
Hyperthermia Serotonergic thermoregulatory disruption plus exertion in hot environments Aggressive cooling, benzodiazepines
Serotonin syndrome Massive serotonin release; potentiated by MAOIs, SSRIs, linezolid, tramadol, dextromethorphan Stop serotonergic agents, benzodiazepines, cooling, cyproheptadine in severe cases
- Rhabdomyolysis, DIC, hepatic injury Downstream of hyperthermia Supportive intensive care
- Post-use dysphoria Serotonin depletion in the days after use Education; the "Tuesday blues" pattern
Harm reduction teaching: hydrate but do not overdrink (about 500 mL per hour maximum while active), take breaks from dancing, avoid combining with serotonergic medications, and use drug-checking services where available, since supply is frequently adulterated with cathinones.
3. PCP and Dissociatives
- Feature PCP Ketamine
- Mechanism NMDA antagonist, also dopaminergic and sigma activity NMDA antagonist
- Duration Hours to days; redistributes from fat Under an hour recreationally
Signature signs Vertical, horizontal or rotary nystagmus ; extreme agitation with analgesia and apparent superhuman strength ; hypertension; violence; may alternate with catatonia Dissociation, "K-hole," transient hypertension and tachycardia
Emergency management Benzodiazepines, low-stimulus environment, physical restraint only with concurrent chemical sedation, monitor for rhabdomyolysis and hyperthermia Usually supportive
Chronic complication Persistent psychosis, cognitive impairment Ulcerative cystitis : urinary frequency, urgency, pain, hematuria, reduced bladder capacity, potentially irreversible contracture; also biliary dilation ("K-cramps")
Exam anchor: vertical nystagmus in an agitated, violent, hypertensive patient who does not respond to pain is the classic PCP presentation. It is one of the few nearly pathognomonic findings in toxicology.
Ketamine's dual identity: intranasal esketamine is FDA-approved for treatment-resistant depression and is administered under a REMS with observation, while non-medical ketamine use carries dependence and urologic risk. Both facts are true and the APRN must be able to hold them together when counseling a patient who reports using ketamine "for depression" from a non-clinical source.
4. Hallucinogen Persisting Perception Disorder (HPPD)
Definition: re-experiencing perceptual symptoms that occurred during intoxication — geometric hallucinations, trails behind moving objects, afterimages, halos, intensified colors, micropsia or macropsia — after the drug's effects have ended, causing distress or impairment.
Reality testing is intact , which distinguishes HPPD from a psychotic disorder.
Must not be attributable to another medical condition (seizure, migraine aura, retinal or optic pathology) or another mental disorder.
Management: reassurance, avoidance of further hallucinogens and of cannabis and stimulants, which commonly exacerbate symptoms; limited evidence supports clonidine, lamotrigine or a benzodiazepine in severe distressing cases. Antipsychotics can worsen symptoms.
5. Other Hallucinogen-Adjacent Agents
- Agent Mechanism Key point
- Salvia divinorum Kappa-opioid agonist Extremely brief, intense dissociation; not detected on routine screens
Dextromethorphan (high dose) NMDA antagonist plus serotonergic activity Serotonin syndrome risk; combination products contain acetaminophen, creating hepatotoxicity risk
Datura / jimsonweed Antimuscarinic "Blind as a bat, mad as a hatter" anticholinergic toxidrome; physostigmine in severe cases
Ibogaine Multiple; used illicitly for opioid detoxification QT prolongation and sudden cardiac death ; not legal in the United States and not a safe detox method
6. Use Disorder and Treatment
DSM-5-TR recognizes phencyclidine use disorder and other hallucinogen use disorder , and lists no withdrawal syndrome for classic hallucinogens. There is no approved pharmacotherapy. Treatment follows general principles: assess co-occurring psychiatric illness carefully (particularly psychosis risk), address the function the drug serves, use motivational and cognitive behavioral approaches, and counsel explicitly on adulteration risk in an unregulated supply.